Shell Asset Management Co. Takes $92,000 Position in SomaLogic, Inc. (NASDAQ:SLGC)

Shell Asset Management Co. purchased a new stake in shares of SomaLogic, Inc. (NASDAQ:SLGCGet Rating) during the 2nd quarter, HoldingsChannel reports. The fund purchased 20,307 shares of the company’s stock, valued at approximately $92,000.

Other hedge funds also recently modified their holdings of the company. Quantbot Technologies LP increased its position in shares of SomaLogic by 24,040.9% during the 1st quarter. Quantbot Technologies LP now owns 5,311 shares of the company’s stock valued at $42,000 after purchasing an additional 5,289 shares during the period. ProShare Advisors LLC acquired a new position in shares of SomaLogic during the 2nd quarter valued at $76,000. Prelude Capital Management LLC acquired a new position in shares of SomaLogic during the 1st quarter valued at $89,000. Engineers Gate Manager LP acquired a new position in shares of SomaLogic during the 1st quarter valued at $104,000. Finally, CTC Capital Management LLC acquired a new position in shares of SomaLogic during the 1st quarter valued at $112,000. 59.29% of the stock is currently owned by institutional investors and hedge funds.

SomaLogic Trading Up 9.1 %

Shares of SLGC stock opened at $3.01 on Friday. SomaLogic, Inc. has a 1-year low of $2.63 and a 1-year high of $13.68. The company has a market capitalization of $552.18 million, a price-to-earnings ratio of -6.54 and a beta of 1.75. The stock’s fifty day simple moving average is $3.08 and its 200-day simple moving average is $4.25.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on SLGC shares. Cowen decreased their target price on SomaLogic to $8.00 in a report on Thursday. Cowen decreased their target price on SomaLogic from $11.00 to $9.00 and set an “outperform” rating on the stock in a report on Tuesday, August 16th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, SomaLogic has an average rating of “Buy” and an average price target of $13.17.

SomaLogic Company Profile

(Get Rating)

SomaLogic, Inc operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.

Read More

Want to see what other hedge funds are holding SLGC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SomaLogic, Inc. (NASDAQ:SLGCGet Rating).

Institutional Ownership by Quarter for SomaLogic (NASDAQ:SLGC)

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.